SUPN (Supernus Pharmaceuticals) FFO


SUPN Supernus Pharmaceuticals Inc SUPN
87 GF Score
Price $45.13
GF Value $40.55
Valuation Modestly Overvalued
View Full Analysis

What is Supernus Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

SUPN
87GF Score
Supernus Pharmaceuticals Inc SUPN
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Supernus Pharmaceuticals (SUPN) Overvalued in 2026?

Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued. The current stock price of $45.13 is trading 11.3% above its estimated GF Value™ of $40.55. GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for SUPN:

  • FFO:
  • GF Value™: $40.55 vs. price of $45.13 (11.3% above fair value)
  • GF Score™: 87/100

No single metric tells the full story. See the SUPN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Supernus Pharmaceuticals Business Description

Other Exchanges 0LB2:UKS49:Germany
Address 9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
87GF Score

Get the complete analysis for SUPN

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$45.13
Price
$40.55
GF Value